Overview
Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018, more than 50% of the global population lives with some form of chronic illness. In 2018, the global prevalence of diabetes (considered to be one of the fastest-growing clinical conditions) was estimated to be around 425 million; likewise, around 450 million people worldwide are suffering from some form of mental health problem and/or neurological disorder. In addition, the World Health Organization (WHO) reported that different forms of cancers account for about 0.6 million deaths annually in the US alone. Over the years, advances in cell biology and regenerative medicine have led to the development of various cell-based therapies, which claim to possess the potential to address several unmet needs related to the treatment of different chronic clinical conditions. However, there are certain evident challenges, such as scarcity of viable donors, inherent immunogenicity, complications related to supply of oxygen / essential nutrients to grafted cells, drug delivery limitations, and the need for frequent re-administration of cells, which have so far restricted the use of cell-based interventions.
Extensive research on cell encapsulation strategies has enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices/carriers. Encapsulated therapy products offer a myriad of advantages, and have been shown to be capable of addressing existing concerns related to cell sourcing, obviating the need for complex surgical procedures, and enabling targeted drug delivery without the need for immunosuppressive follow-on regimens. In fact, since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in this domain. Stakeholders have also received significant support from both private and public investors. However, the commercial success of such products is still dependent on ongoing clinical studies, as no such therapy has yet been approved.
Scope of the Report
The ‘Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030’ report features an extensive study of the current market landscape and the future potential of encapsulated cell therapies and affiliated technologies. It is worth mentioning that the study also provides insights on therapy products wherein other active drug substances have been encapsulated within living cells. Amongst other elements, the report features:
- A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications.
- Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseeable future.
- An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of the number of patents filed/granted), and current intellectual property-related benchmarks and valuation.
- A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
- An analysis of the partnerships that have been established in the domain in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and/or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
- An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. The report also features a detailed study on the various grants that have been awarded to research institutes in this field.
- An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates, and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangiectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapeutic products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.
Table of Contents
Executive Summary
Chapter Outlines
- Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view of the likely evolution of encapsulated cell therapies and affiliated technologies market in the mid to long term.
- Chapter 3 is an introductory chapter that presents a general overview of cell-based therapies and the intricacies of their development and administration, along with information on the key challenges associated with them. Further, it features a detailed discussion on cell encapsulation, including a comprehensive history of development, and information on different types of cell encapsulation methods and materials. It also features a discussion on the key advantages/challenges associated with encapsulated cell therapies and affiliated technologies, providing information on their potential usability across different application areas. Further, the chapter features a discussion on the key growth drivers and roadblocks related to cell encapsulation technologies and their use in treating various chronic conditions.
- Chapter 4 includes information on more than 40 encapsulated cell therapies and affiliated technologies that are currently being developed by industry players for treating different chronic conditions. It features a comprehensive analysis of pipeline therapies and technologies, highlighting the target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration. The chapter also highlights the contributions of various stakeholder companies that are developing novel encapsulation methods/techniques for use in storage and transportation of cells, as well as other applications. Additionally, the chapter features information on the initiatives undertaken by big pharmaceutical companies and academic players within this domain.
- Chapter 5 includes elaborate profiles of industry players that are currently engaged in the clinical development of their proprietary encapsulated cell therapies for the treatment of metabolic disorders; each profile features an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key clinical trial results. Each profile also includes a list of recent developments, the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. Further, for developers with early stage (preclinical) candidates, we have presented brief profiles, highlighting key details about the company, product portfolio, recent developments, and the likely roadmap / future plans related to the development and commercialization of their products (if available).
- Chapter 6 includes elaborate profiles of industry players that are currently engaged in the clinical development of their proprietary encapsulated cell therapies for the treatment of non-metabolic disorders; each profile features an overview of the company, its financial information (if available), and a detailed description of its product (s), highlighting mechanism of action, current development status, and key clinical trial results. Each profile also includes a list of recent developments, the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. Further, for developers with early stage (preclinical) candidates, we have presented brief profiles, highlighting key details about the company, product portfolio, recent developments, and the likely roadmap / future plans related to the development and commercialization of their products (if available).
- Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been published since 2013 related to the cell encapsulation domain. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of the number of patents filed/granted), and current intellectual property-related benchmarks and valuation.
- Chapter 8 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, targeted therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
- Chapter 9 features an elaborate discussion and analysis of partnerships/collaborations that have been established in the domain in the period 2013-2018. It includes a brief description of various types of partnership models (such as product development/commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers/acquisitions, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to encapsulated cell therapies and affiliated technologies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
- Chapter 10 provides information on funding instances and investments that have been made within the cell encapsulation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies between 2013 and 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
- Chapter 11 provides a detailed analysis of academic grants that have been awarded to support research related to encapsulated cell therapies and affiliated technologies. For the purpose of this analysis, we considered those academic grants that have been awarded within this domain since 2013. In addition to highlighting key funding institutes, the chapter provides several emerging encapsulation methods, target indications, and type of cells, across which the majority of the research work is currently focused.
- Chapter 12 features an insightful analysis, highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers, based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to take their proprietary therapies/technologies from concept to the market with the help the appropriate partner entities.
- Chapter 13 features a comprehensive market forecast, highlighting the future potential of this market until 2030 based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates, and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangiectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific).
- Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report and expressed our independent opinion related to the research and analysis described in the previous chapters.
- Chapter 15 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Alexander Scheer (Chief Scientific Officer, Erytech Pharma), Manuel Pires (Business Developer, Defymed), Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem), Mick McLean (Chief Executive Officer, Atelerix), Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals), William L Rust (Founder and Chief Executive Officer, Seraxis), and Yuval Avni (Former Chief Executive Officer, Beta-O2 Technologies).
- Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
- Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.
Companies Mentioned
- 24Haymarket
- 3P Biopharmaceuticals
- 4D Pharma
- Aarhus University Hospital
- Acer Therapeutics
- Activartis Biotech
- Activate Immunotherapy
- Adaptimmune
- Adicet Bio
- ADIRA
- Aduro Biotech
- Advent Bioservices
- Agency for Science, Technology and Research
- AgenTus Therapeutics
- Aldagen
- Allele Biotechnology & Pharmaceuticals
- Alliance for Regenerative Medicine
- Allife Medical Science and Technology
- Allogene Therapeutics
- Alsace BioValley
- Altor BioScience
- ALTuCELL
- AlzeCure Pharma
- Amgen
- Amphera
- AMVALOR
- Anhui Kedgene Biotechnology
- ANI Pharmaceuticals
- Anterogen
- apceth Biopharma
- Arbele
- ARCH Venture Partners
- Argos Therapeutics
- Asahi Glass Company
- ASAP Ventures
- Asset Management Partners
- Astellas Institute for Regenerative Medicine
- Astellas Pharma
- Asterias Biotherapeutics
- AstraZeneca
- Atara Biotherapeutics
- Atelerix
- Athersys
- Atlanpole
- Atlantic Bio GMP
- Atreca
- Aurora Biopharma
- Australian Foundation for Diabetes Research
- Austrianova Singapore
- Autolus
- AVAX Technologies
- Axil Scientific
- Azellon Cell Therapeutics
- Bain Capital Life Sciences
- Bascom Palmer Eye Institute
- Basic Pharma
- Batavia Bioservices
- Bavarian Nordic
- Baxalta
- Baxter International
- Baylor College of Medicine
- BBS Nanotechnology
- Beijing Biohealthcare Biotechnology
- Beijing Doing Biomedical
- Beijing Immunochina Medical Science & Technology
- Beijing Sanwater Biological Technology
- Beijing Tricision Biotherapeutics
- Beike Biotechnology
- Bell Biosystems
- Bellicum Pharmaceuticals
- Beta-Cell
- Beta-O2 Technologies
- Betalin Therapeutics
- Beyond Type 1
- Bio Elpida
- BioAtla
- BioCardia
- Bioencapsulation Research Group
- Bioglex
- Bioinova
- Bioinspired Solutions
- BioLamina
- Bioneer
- BioNTech
- Biopredic
- BioRestorative Therapies
- BioTalentum
- BIOTECanada
- Biotechnology Innovation Organization
- bluebird bio
- Bone Therapeutics
- Bpifrance
- Brainstorm Cell Therapeutics
- Brammer Bio
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Broad Institute
- Brown University
- Caladrius Biosciences
- California Institute for Regenerative Medicine
- Calvert Crossland
- Cambridge Enterprise
- Capella Science
- Capricor Therapeutics
- Capsulæ
- Captain T Cell
- CardioCell
- Carina Biotech
- CARsgen Therapeutics
- Cartherics
- Casa Sollievo della Sofferenza
- Case Western Reserve University
- CBD Solutions
- Celgene
- Celixir
- Cell and Gene Therapy Catapult
- Cell Biotech
- Cell Cure Neurosciences
- Cell Genesys
- Cell Medica
- Cell Tech Pharmed
- Cellectis
- CellforCure
- Cellin Technologies
- CELLINK
- CellMed Health
- CellPraxis Bioengeneering
- CellProtect Biotechnology
- CellProtect Nordic Pharmaceuticals
- CellProthera
- Cells for Cells
- Cellular Biomedicine Group
- Cellular Dynamics International
- Cellular Therapeutics
- Celularity
- Celyad
- Censo Biotechnologies
- Centre for Brain Research at the University of Auckland
- Centre for Cell and Gene Processing
- Centre for Commercialization of Regenerative Medicine
- Cesca Therapeutics
- Chamow & Associates
- Chardan Capital Markets
- Chengdu MedGenCell
- Children's Hospital of Philadelphia
- Children's Medical Center
- CiMaas
- Clinical Network Services
- Cognate Bioservices
- Conkwest
- Cook Myosite
- Corestem
- Cornell University
- Covance
- Cowen Healthcare Investments
- CRISPR Therapeutics
- CRMI
- Cryosite
- CTI Clinical Trial and Consulting Services
- Cytopeutics
- Cytori Therapeutics
- Cytosen Therapeutics
- CytoSolv
- Cytovac
- CyTuVax
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- DanDrit Biotech
- DCPrime
- Defymed
- Delta-Vir
- Dendreon
- DePuy Synthes
- Diatranz Otsuka
- DiscGenics
- Dolomite Microfluidics
- Duke-NUS Medical School
- Durham University
- East West Capital Partners
- Ecomeris
- Eight Roads Ventures
- Eli Lilly
- Elios Therapeutics
- EMMES
- Emory University
- Encellin
- Endocyte
- Epigem
- EryDel
- Erytech Pharma
- Ethicon
- Eunice Kennedy Shriver National Institute of Child Health & Human Development
- Eureka Therapeutics
- European Foundation for the Study of Diabetes
- Eutilex
- Evotec
- Exostem Biotec
- Exploit Technologies
- F-Prime Capital
- F1 Oncology
- Facet Life Sciences
- Fate Therapeutics
- Ferrer Internacional
- Fibrocell Technologies
- Fisher BioServices
- Five Prime Therapeutics
- Flagship Pioneering
- Focus Gestioni
- Formula Pharmaceuticals
- Fortress Biotech
- Fox Chase Cancer Center
- French National Institute of Health and Medical Research
- FronTier Merchant Capital
- Gabriel Investments
- Gadeta
- Gamida Cell
- GC Cell
- Genentech
- Genextra
- Genzyme
- Georgia Institute of Technology
- GigaGen
- Giner Labs
- GlaxoSmithKline
- Global Cell Med
- Gloriana Therapeutics
- Glycostem Therapeutics
- Gradalis
- Graybug Vision
- Green Cross
- Greenwood Way Capital
- GRI Bio
- Guangzhou Trinomab Biotech
- H2M Capital
- Harvard Stem Cell Institute
- Heat Biologics
- Hebei Senlang Biotechnology
- Hebrew University of Jerusalem
- Hemostemix
- HengRui YuanZheng Bio-Technology
- Histocell
- Histogenics
- Hitachi Chemical Advanced Therapeutics Solutions
- Holostem Terapieavanzate
- Howard Hughes Medical Institute
- Hunan Zhaotai Yongren Biotech
- I&L Biosystems
- iCarTAB BioMed
- iCell Gene Therapeutics
- Imaging Endpoints
- Immatics
- Immetacyte
- Immune Therapeutics
- Immunicum
- ImmunoCellular Therapeutics
- Immunocore
- Immunovative Therapies
- Immutep
- IMpacting Research, INnovation and Technology
- ImStem Biotechnology
- Imvax
- iNanoBIT
- Incysus
- Inno Biologics
- Innogest Capital
- Innovative Cellular Therapeutics
- Inovio Pharmaceuticals
- inRegen
- Institute for Basic Sciences
- Institute of Virology at the University of Veterinary Medicine
- Intellia Therapeutics
- Intrexon
- Iovance Biotherapeutics
- Iowa State University
- IRCAD France
- Israel Innovation Authority
- Isto Biologics
- iThera Medical
- Ivy Life Sciences
- Janssen Biotech
- Japan Tissue Engineering
- JDRF
- Jean Lamour Institute
- Johns Hopkins University
- Johnson & Johnson
- Joslin Diabetes Center
- Juno Therapeutics
- Juvenile Diabetes Research Foundation
- JW Biotechnology
- JW CreaGene
- Kadimastem
- Kangstem Biotech
- Kangwon National University
- Karolinska Institutet
- KBI Biopharma
- King's College London
- Kiromic
- Kite Pharma
- KTH Royal Institute of Technology
- Legend Biotech
- Leland Stanford Junior University
- Leucid Bio
- Lifecells
- Likarda
- Lincoln Park Capital Fund
- Lion TCR
- Living Cell Technologies
- Living Pharma
- Longeveron
- Lonza
- Lowy Medical Research Institute
- Ludwig Maximilian University of Munich
- Lund University
- LV Prasad Eye Institute
- Léon Bérard Center
- Maine Medical Center
- Marino Biotechnology
- Marker Therapeutics
- Maryland Technology Development
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- MaSTherCell
- MaxCyte
- MaxiVAX
- Mayo Clinic
- McGill University
- MED-EL
- Medeor Therapeutics
- Medical University of South Carolina
- Medicyte
- MediGene
- MedImmune
- MEDINET
- Medipost
- Mediso
- Medpace
- Medtronic
- MedVax Technologies
- Medytox
- Merck Serono
- Mesoblast
- Michael J Fox Foundation for Parkinson’s Research
- MicroMecha
- Miltenyi Biotec
- Minovia Therapeutics
- Moderna Therapeutics
- MolecuVax
- MolMed
- Moraga Biotechnology
- MPM Capital
- Multimmune
- Mustang Bio
- Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering
- NantKwest
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Council of Science and Technology, Mexico
- National Eye Institute
- National Heart, Lung, and Blood Institute
- National Institute of Agricultural Research
- National Institute of Allergy and Infectious Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Dental and Craniofacial Research
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of General Medical Sciences
- National Institute of Neurological Disorders and Stroke
- National Institute of Rehabilitation Training and Research
- National Institute on Aging
- National Institute on Deafness and Other Communication Disorders
- National Institutes of Health
- National Institutes of Health Clinical Center
- National Research Council of Canada
- National Science Foundation
- Nemours Alfred I duPont Hospital for Children
- Neopharm
- Network IR
- Neuralstem
- Neurotech Pharmaceuticals
- New York Blood Center
- Newable Private Investing
- Newcastle University
- NewLink Genetics
- Nikon CeLL innovation
- Nimesis Technology
- Nkarta Therapeutics
- Nohla Therapeutics
- Noile-Immune Biotech
- Northeastern University
- Northern Therapeutics
- Northwest Biotherapeutics
- Novadip Biosciences
- NovaMatrix
- Novartis
- Novella Clinical
- Noveome Biotherapeutics
- Novo Nordisk
- Novoron Bioscience
- NSF Engineering Research Center for Cell Manufacturing Technologies
- Nuffield Department of Surgical Sciences at the Oxford University
- Ohio State University
- OhioHealth
- OiDE BetaRevive
- Omega Ophthalmics
- OncoBioMed
- Oncodesign
- One Cell Systems
- OneVax
- Ontario Institute for Regenerative Medicine
- Opexa Therapeutics
- Ophysio
- OptoRobotix
- Orchard Therapeutics
- Oregon Health and Science University
- Orphan Technologies
- Osiris Therapeutics
- Otsuka Pharmaceutical Factory
- Oxford BioMedica
- Oxford Technology Management
- Parkwalk Advisors
- Paul Langerhans Institut Dresden
- PCI Services
- PDC*line Pharma
- Peak Capital Advisors
- PersonGen BioTherapeutics
- Pfizer
- PharmaBio
- PharmaCell
- PharmaCyte Biotech
- Pharmicell
- Philadelphia VA Medical Center
- Philips Healthcare
- Pinze Lifetechnology
- Pique Therapeutics
- PL BioScience
- Pluristem Therapeutics
- Poseida Therapeutics
- Praxis Pharmaceutical
- Precision BioSciences
- Pregene (ShenZhen) Biotechnology
- Profusa
- Promethera Biosciences
- Providence Investments
- Queen’s University
- RA Capital Management
- Ramcon
- Ramot
- Regeneris Medical
- Regeneron
- Regeneus
- Regenics
- ReNeuron
- RHEACELL
- Rice University
- Roger Williams Medical Center
- Roslin Cells
- Rubius Therapeutics
- Sanderling Ventures
- Sanofi
- Saronic Biotechnology
- Scientist.com
- Sclnow Biotechnology
- Scottish Investment Bank
- Seattle Genetics
- SEMIA
- Semma Therapeutics
- Sentien Biotechnologies
- Seraxis
- Sernova
- Servier
- Shanghai Bioray Laboratory
- Shanghai GeneChem
- Shanghai Houchao Biotechnology
- Shanghai iCELL Biotechnology
- Shanghai Longyao Biotechnology
- Shanghai Unicar-Therapy Bio-medicine Technology
- Shenzhen BinDeBio
- Shenzhen Hornetcorn Biotechnology
- Sherpa InnoVentures
- Shionogi
- Sidney Kimmel Cancer Center
- Sigilon Therapeutics
- Sigma-Aldrich
- Single Cell Technology
- Sinobioway Cell Therapy
- Skanderbeg Capital Advisors
- SMT Bio
- Sofinnova Partners
- Sorrento Therapeutics
- Sotio
- Sphere Fluidics
- SpherIngenics
- SQZ Biotechnologies
- Stanford University
- Statistecol Consultants
- Stem Cell Arabia
- StemBios Technologies
- STEMCELL Technologies
- Stemedica Cell Technologies
- Stempeutics Research
- Super-T Cell Cancer
- Surface Oncology
- Swiss Cancer League
- Swiss Group for Clinical Cancer Research
- Sylvatica Biotech
- SymbioCellTech
- Symbiose Biomaterials
- Tactiva Therapeutics
- Taiwan Bio Therapeutics
- Takara Bio
- Takeda Pharmaceutical
- Targazyme
- TC BioPharm
- TCR2 Therapeutics
- Technocampus Group
- Tella
- Terumo
- Tessa Therapeutics
- Teva Pharmaceutical
- TheraCyte
- Thermo Fisher Scientific
- Thomas Jefferson University
- Tianhe Stem Cell Biotechnologies
- Tianjin Ever Union Biotechnology
- TiGenix
- TILT Biotherapeutics
- Tmunity Therapeutics
- TNK Therapeutics
- TotipotentRX
- TPG Capital
- TRACT Therapeutics
- TransCure BioServices
- Translational Drug Development
- Trinity College Dublin
- Triumvira Immunologics
- Tufts University
- Tulane University
- TVAX Biomedical
- TxCell
- United States Department of Veterans Affairs
- Universal Cells
- University Health Network
- University of Alabama, Birmingham
- University of Alberta
- University of Arizona
- University of British Columbia
- University of California
- University of Cambridge
- University of Chicago
- University of Connecticut
- University of Delaware
- University of Florida
- University of Life Sciences, Lublin
- University of Lorraine
- University of Los Andes
- University of Louvain
- University of Massachusetts Medical School
- University of Miami
- University of Michigan
- University of North Carolina
- University of Northern Colorado
- University of Pennsylvania
- University of Perugia
- University of Pittsburgh
- University of Rochester
- University of Strathclyde
- University of Texas Southwestern Medical Center
- University of Veterinary Medicine, Vienna
- University of Virginia
- University of Wisconsin Madison
- University of Zurich
- Unum Therapeutics
- Uppsala University Hospital
- US Department of Defense
- US Stem Cell
- UZ Brussel
- UZ Leuven
- Vaccinogen
- Valorial
- Vanderbilt University Medical Center
- VEGEPOLYS
- Vericel
- ViaCyte
- ViCapsys
- ViroMed
- ViruSure
- Viscofan BioEngineering
- Vissum
- Vor Biopharma
- W L Gore & Associates
- Waisman Biomanufacturing
- Wake Forest School of Medicine
- Werth Family Investment Associates
- Whitehead Institute for Biomedical Research
- WiSP Wissenschaftlicher Service Pharma
- Wuhan Sian Medical Technology
- Wuxi AppTec
- Wyss Institute for Biologically Inspired Engineering
- Xcelthera
- Xellbiogene
- XEME Biopharma
- YposKesi
- Zelluna Immunotherapy
- Zhongguancun Lianchuang Medical Engineering Transformation Center
- Zimmer Biomet
- ZIOPHARM Oncology
Methodology
LOADING...